Form 4: Cytek CFO Reports RSU Vesting and Stock Transactions

Cytek Biosciences' CFO, William D. McCombe, reported the vesting of Restricted Stock Units and subsequent stock transactions, including tax-related dispositions.

Summary

• William D. McCombe, Chief Financial Officer of Cytek Biosciences, Inc. (CTKB), reported transactions on November 18, 2025.
• McCombe acquired 6,320 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• An additional 13,051 shares of common stock were acquired through the vesting of a separate RSU award.
• To satisfy tax withholding obligations related to the vesting of the first RSU award, 2,032 shares of common stock were disposed of at a price of $5.53 per share.
• For the second RSU award, 4,196 shares of common stock were disposed of at a price of $5.53 per share for tax withholding.
• Following these transactions, McCombe directly beneficially owns 71,859 shares of common stock.
• McCombe also directly beneficially owns 63,209 and 174,014 Restricted Stock Units, totaling 237,223 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the CFO acquired a significant number of shares through RSU vesting, demonstrating continued equity ownership. The disposition of shares for tax purposes is a standard, neutral event.

Positives

• The Chief Financial Officer acquired a total of 19,371 shares of common stock through the vesting of Restricted Stock Units, indicating continued equity ownership and alignment with shareholder interests.

Negatives

• A total of 6,228 shares of common stock were disposed of to cover tax withholding obligations, reducing the net shares acquired from the RSU vesting.

Future Outlook

The remaining Restricted Stock Units held by the CFO are subject to multi-year vesting schedules. For one RSU award, vesting occurs on May 18, August 18, November 18, and March 10 annually until fully vested. For another RSU award, vesting occurs on May 18, August 18, November 18, and March 10 annually until fully vested.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies that utilize equity-based incentive plans.

Stakeholder Impact

• Shareholders: This routine transaction indicates continued alignment of executive interests with shareholder value through equity compensation, with no immediate material impact on company operations or strategy.
• Employees: Reflects standard executive compensation practices, which may influence broader compensation strategies within the company.

Next Steps

• Future vesting events for the remaining Restricted Stock Units will occur according to the established schedules on May 18, August 18, November 18, and March 10 of subsequent years.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and subsequent tax-related share dispositions. Such events are part of standard executive compensation and do not typically provide new fundamental information that would alter an investment thesis or warrant a change in recommendation. The net effect is an increase in the executive's direct shareholdings, which is generally viewed as a neutral to slightly positive signal of alignment.

Keywords

Cytek Biosciences, CTKB, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Transactions, William D. McCombe